Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Treasury Shares: 2011-2024

Historic Treasury Shares for Cytokinetics (CYTK) over the last 14 years, with Dec 2024 value amounting to $1.9 million.

  • Cytokinetics' Treasury Shares rose 35.68% to $1.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.9 million, marking a year-over-year increase of 35.68%. This contributed to the annual value of $1.9 million for FY2024, which is 35.68% up from last year.
  • According to the latest figures from FY2024, Cytokinetics' Treasury Shares is $1.9 million, which was up 35.68% from $1.4 million recorded in FY2023.
  • Cytokinetics' 5-year Treasury Shares high stood at $1.9 million for FY2024, and its period low was $1.1 million during FY2020.
  • Moreover, its 3-year median value for Treasury Shares was $1.4 million (2023), whereas its average is $1.5 million.
  • Per our database at Business Quant, Cytokinetics' Treasury Shares declined by 14.18% in 2022 and then skyrocketed by 35.68% in 2024.
  • Cytokinetics' Treasury Shares (Yearly) stood at $1.1 million in 2020, then climbed by 26.70% to $1.4 million in 2021, then dropped by 14.18% to $1.2 million in 2022, then rose by 13.21% to $1.4 million in 2023, then surged by 35.68% to $1.9 million in 2024.